language
Developers are recombining or sharpening established drugs, molecules and mechanisms to create a new generation of neurology therapies.
Neurology is back. A suite of high profile approvals — from Biogen and Eli Lilly’s Alzheimer’s disease drugs to Bristol Myers Squibb’s schizophrenia treatment Cobenfy (xanomeline and trospium chloride) and, most recently, Vertex Pharmaceuticals’ non-opioid pain treatment Journavx (suzetrigine) — has placed the category firmly back onto dealmakers’ radars.
News Center
Want more product service? Leave us a message
We will contact you within one working day. Please pay attention to your email.
